No HIV transmission among women who were on HAART at the time of invasive testing
FRIDAY, July 1, 2016 (HealthDay News) — For pregnant women with HIV infection, invasive prenatal testing does not increase the risk of vertical transmission, according to a study published online June 20 in BJOG: An International Journal of Obstetrics & Gynaecology.
Marco Floridia, M.D., from the Istituto Superiore di Sanità in Rome, and colleagues conducted an observational study among pregnant women with HIV to examine the rates of amniocentesis and chorionic villus sampling and the outcomes associated with those procedures. Data were examined for 2,065 pregnancies in women with HIV.
The researchers found that 5.5 percent of participants underwent invasive testing. In 87.6 percent of cases, the procedures were conducted under antiretroviral treatment, with the proportion of tests performed under highly active antiretroviral therapy (HAART) increasing significantly over time (100 percent in 2011 to 2015). There were three intrauterine deaths (2.6 percent), and 14 pregnancies were terminated because of the presence of fetal anomalies. Among the 88 live newborns with information available on HIV status, there were two HIV transmissions (2.3 percent). Among women who were on HAART at the time of invasive testing, there was no HIV transmission, and there were no cases after 2005.
“The findings reinforce the assumption that invasive prenatal testing does not increase the risk of HIV vertical transmission among pregnant women under suppressive antiretroviral treatment,” the authors write.
Copyright © 2016 HealthDay. All rights reserved.
